The Four Domains of Patient Participation in the HEOR process
In order to make HEOR more accessible to patients, we will need to engage patient communities earlier, deepen those engagements, and sustain them. Greater accessibility will create a virtuous cycle in which engagement will make the HEOR process more efficient, leading to faster and more informed decision-making regarding access to new interventions. This, in turn, has the potential to accelerate outcomes.
Such engagement will require effort from both sides. To build trust and partnership between stakeholders who come from different worlds, we will need to stay true to our shared ambition to improve outcomes for people living with disease.
Patients who trust pharmaceutical companies are more likely to participate in pharmaceutical research, of course, but the
benefits of this participation ultimately accrue to the patients themselves. Those who suffer the burden of disease will not only have access to the more effective therapies that pharmaceutical research yields, but will also gain access to treatments that were designed with their physical and emotional needs, preferences and quality of life in mind. HEOR is a multidisciplinary and multifaceted field. To help stakeholders understand how and where to involve patient communities, we’ve identified the following four domains of patient participation in the HEOR process. These domains extend across every stage of the project lifecycle, because patient involvement is just as important at a project’s inception as it is when conveying the results – and explaining why they matter.
In order to make HEOR more accessible to patients, we will need to engage patient communities earlier, deepen those engagements, and sustain them. Greater accessibility will create a virtuous cycle in which engagement will make the HEOR process more efficient, leading to faster and more informed decision-making regarding access to new interventions. This, in turn, has the potential to accelerate outcomes.
Such engagement will require effort from both sides. To build trust and partnership between stakeholders who come from different worlds, we will need to stay true to our shared ambition to improve outcomes for people living with disease.
Patients who trust pharmaceutical companies are more likely to participate in pharmaceutical research, of course, but the benefits of this participation ultimately accrue to the patients themselves. Those who suffer the burden of disease will not only have access to the more effective therapies that pharmaceutical research yields, but will also gain access to treatments that were designed with their physical and emotional needs, preferences and quality of life in mind. HEOR is a multidisciplinary and multifaceted field. To help stakeholders understand how and where to involve patient communities, we’ve identified the following four domains of patient participation in the HEOR process. These domains extend across every stage of the project lifecycle, because patient involvement is just as important at a project’s inception as it is when conveying the results – and explaining why they matter.